18221656311
聯(lián)系人:錢經(jīng)理
電 話:18221656311
手 機(jī):18221656311
地 址:上海市松江臨港科技城漢橋文化科技園B座
郵 編:200093
傳 真:021-64881400
郵 箱:2885617636@qq.com
阿儀網(wǎng)商鋪:http://www.app17.com/c58469/
手機(jī)網(wǎng)站:m.hybiosh.com
閱讀次數(shù):1565 發(fā)布時(shí)間:2012/8/21 9:01:52
澳大利亞生物工程與米技術(shù)研究所副教授 Ernst Wolvetang領(lǐng)導(dǎo)的研究小組與來(lái)自澳大利亞昆士蘭醫(yī)學(xué)研究所(Queensland Institute of Medical Research, QIMR)和昆士蘭大學(xué)臨床研究中心(University of Queensland's Centre for Clinical Research, UQCCR)的研究人員合作開(kāi)展研究,并且是次將來(lái)自患有AT的病人身上的皮膚細(xì)胞重編程為誘導(dǎo)性多能干細(xì)胞(induced pluripotent stem cells,iPSCs),這樣他們能夠研究潛在治療方法的有效性。
這種重編程過(guò)程涉及提取皮膚細(xì)胞,產(chǎn)生多能性干細(xì)胞,然后誘導(dǎo)它們變成腦細(xì)胞以便用于實(shí)驗(yàn)室研究。
患有AT的病人容易患上癌癥和大腦退化性疾病,這是因?yàn)樵谒麄凅w內(nèi)一個(gè)用來(lái)識(shí)別和修復(fù)DNA損傷的基因存在缺陷。
副教授Wolvetang說(shuō),將來(lái)自患有AT的兒童的皮膚細(xì)胞進(jìn)行重編程的能力為人們提供一種可以自我更新的細(xì)胞來(lái)源來(lái)研究這種神經(jīng)退化性疾病和找到治療它的藥物。
副教授Wolvetang說(shuō),“下一步就是校正源自這些病人的誘導(dǎo)性多能干細(xì)胞(iPSCs)中的基因突變,然后將這些經(jīng)過(guò)校正的干細(xì)胞轉(zhuǎn)化為腦細(xì)胞和血細(xì)胞,并且還要證實(shí)它們能夠替換導(dǎo)致這種疾病產(chǎn)生的缺陷性細(xì)胞。移植這些經(jīng)過(guò)校正的細(xì)胞(仍然需要多年才可能實(shí)現(xiàn))或者利用這項(xiàng)研究中產(chǎn)生的細(xì)胞而開(kāi)發(fā)出的藥物可能有助于治療這種疾病。”
研究人員有望在一到兩年內(nèi)開(kāi)始藥物篩選,但是動(dòng)物測(cè)試必須在它們能夠用于人類治療之前完成。
共濟(jì)失調(diào)性毛細(xì)血管擴(kuò)張癥(AT)是一種罕見(jiàn)的遺傳性疾病,它導(dǎo)致嚴(yán)重性殘疾,包括運(yùn)動(dòng)和協(xié)調(diào)存在困難,免疫系統(tǒng)受到削弱;加蠥T的病人很容易遭受感染,而且患上癌癥的風(fēng)險(xiǎn)不斷增加。它的發(fā)病率在1/300000到1/100000;加羞@種疾病的病人在十幾歲初期就經(jīng)常坐在輪椅上,而且當(dāng)他們到達(dá)二十多歲時(shí),它是致命性的。
研究人員將他們的研究成果發(fā)表在Stem Cells Translational Medicine期刊上。
doi:10.5966/sctm.2012-0024
PMC:
PMID:
Induced Pluripotent Stem Cells from Ataxia-Telangiectasia Recapitulate the Cellular Phenotype
Sam Naylera,b, Magtouf Gateib, Sergei Kozlovb, Richard Gattic, Jessica C. Mard, Christine A. Wellsa, Martin Lavinb,e and Ernst Wolvetang
Pluripotent stem cells can differentiate into every cell type of the human body. Reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) therefore provides an opportunity to gain insight into the molecular and cellular basis of disease. Because the cellular DNA damage response poses a barrier to reprogramming, generation of iPSCs from patients with chromosomal instability syndromes has thus far proven to be difficult. Here we demonstrate that fibroblasts from patients with ataxia-telangiectasia (A-T), a disorder characterized by chromosomal instability, progressive neurodegeneration, high risk of cancer, and immunodeficiency, can be reprogrammed to bona fide iPSCs, albeit at a reduced efficiency. A-T iPSCs display defective radiation-induced signaling, radiosensitivity, and cell cycle checkpoint defects. Bioinformatic analysis of gene expression in the A-T iPSCs identifies abnormalities in DNA damage signaling pathways, as well as changes in mitochondrial and pentose phosphate pathways. A-T iPSCs can be differentiated into functional neurons and thus represent a suitable model system to investigate A-T-associated neurodegeneration. Collectively, our data show that iPSCs can be generated from a chromosomal instability syndrome and that these cells can be used to discover early developmental consequences of ATM deficiency, such as altered mitochondrial function, that may be relevant to A-T pathogenesis and amenable to therapeutic intervention.
上海恒遠(yuǎn)生物科技有限公司出售各種進(jìn)口高端elisa試劑盒,生物試劑,血清,標(biāo)準(zhǔn)品。質(zhì)量上乘,歡迎咨詢。
掃一掃,關(guān)注我們!
首 頁(yè)| 公司介紹| 產(chǎn)品展示| 公司新聞| 技術(shù)文章| 聯(lián)系我們| 客戶留言
阿儀網(wǎng) 設(shè)計(jì)制作,未經(jīng)允許翻錄必究. 聯(lián)系人:錢經(jīng)理 聯(lián)系電話:18221656311 ICP備案號(hào):滬ICP備11004148號(hào)-11 總訪問(wèn)量:7702616 管理登錄
主營(yíng)產(chǎn)品:ELISA試劑盒,人ELISA試劑盒,大鼠ELISA試劑盒,小鼠ELISA試劑盒,裸鼠ELISA試劑盒,倉(cāng)鼠ELISA試劑盒,標(biāo)準(zhǔn)品,培養(yǎng)基和生物試劑等